Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial

黄斑变性 耐受性 医学 队列 视力 队列研究 脉络膜新生血管 不利影响 眼科 内科学 外科
作者
Jeffrey S. Heier,Saleema Kherani,Shilpa J. Desai,Pravin U. Dugel,Shalesh Kaushal,Seng H. Cheng,Cheryl Delacono,Annie Purvis,Susan Richards,Annaig Le-Halpere,John T. Connelly,Samuel C. Wadsworth,Rafael Varona,Ronald Buggage,Abraham Scaria,Peter A. Campochiaro
出处
期刊:The Lancet [Elsevier]
卷期号:390 (10089): 50-61 被引量:189
标识
DOI:10.1016/s0140-6736(17)30979-0
摘要

Long-term intraocular injections of vascular endothelial growth factor (VEGF)-neutralising proteins can preserve central vision in many patients with neovascular age-related macular degeneration. We tested the safety and tolerability of a single intravitreous injection of an AAV2 vector expressing the VEGF-neutralising protein sFLT01 in patients with advanced neovascular age-related macular degeneration.This was a phase 1, open-label, dose-escalating study done at four outpatient retina clinics in the USA. Patients were assigned to each cohort in order of enrolment, with the first three patients being assigned to and completing the first cohort before filling positions in the following treatment groups. Patients aged 50 years or older with neovascular age-related macular degeneration and a baseline best-corrected visual acuity score of 20/100 or less in the study eye were enrolled in four dose-ranging cohorts (cohort 1, 2 × 108 vector genomes (vg); cohort 2, 2 × 109 vg; cohort 3, 6 × 109 vg; and cohort 4, 2 × 1010 vg, n=3 per cohort) and one maximum tolerated dose cohort (cohort 5, 2 × 1010 vg, n=7) and followed up for 52 weeks. The primary objective of the study was to assess the safety and tolerability of a single intravitreous injection of AAV2-sFLT01, through the measurement of eye-related adverse events. This trial is registered with ClinicalTrials.gov, number NCT01024998.19 patients with advanced neovascular age-related macular degeneration were enrolled in the study between May 18, 2010, and July 14, 2014. All patients completed the 52-week trial period. Two patients in cohort 4 (2 × 1010 vg) experienced adverse events that were possibly study-drug related: pyrexia and intraocular inflammation that resolved with a topical steroid. Five of ten patients who received 2 × 1010 vg had aqueous humour concentrations of sFLT01 that peaked at 32·7-112·0 ng/mL (mean 73·7 ng/mL, SD 30·5) by week 26 with a slight decrease to a mean of 53·2 ng/mL at week 52 (SD 17·1). At baseline, four of these five patients were negative for anti-AAV2 serum antibodies and the fifth had a very low titre (1:100) of anti-AAV2 antibodies, whereas four of the five non-expressers of sFLT01 had titres of 1:400 or greater. In 11 of 19 patients with intraretinal or subretinal fluid at baseline judged to be reversible, six showed substantial fluid reduction and improvement in vision, whereas five showed no fluid reduction. One patient in cohort 5 showed a large decrease in vision between weeks 26 and 52 that was not thought to be vector-related.Intravitreous injection of AAV2-sFLT01 seemed to be safe and well tolerated at all doses. Additional studies are needed to identify sources of variability in expression and anti-permeability activity, including the potential effect of baseline anti-AAV2 serum antibodies.Sanofi Genzyme, Framingham, MA, USA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
illmaticRui发布了新的文献求助10
刚刚
myl发布了新的文献求助10
2秒前
不配.应助YC采纳,获得10
2秒前
4秒前
6秒前
淡漠发布了新的文献求助10
9秒前
peng发布了新的文献求助10
11秒前
12秒前
小朋友发布了新的文献求助10
12秒前
no汤圆芋圆完成签到,获得积分10
15秒前
Chou完成签到,获得积分10
15秒前
jianglanfyf完成签到,获得积分10
16秒前
16秒前
赘婿应助快乐寄风采纳,获得10
18秒前
小朋友完成签到,获得积分10
18秒前
S飞完成签到 ,获得积分10
21秒前
123完成签到 ,获得积分10
22秒前
RobertChen完成签到,获得积分10
24秒前
24秒前
28秒前
28秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
丘比特应助科研通管家采纳,获得10
30秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
30秒前
科研通AI2S应助科研通管家采纳,获得10
30秒前
852应助科研通管家采纳,获得10
30秒前
香蕉觅云应助科研通管家采纳,获得30
30秒前
科目三应助科研通管家采纳,获得10
30秒前
orixero应助科研通管家采纳,获得10
30秒前
斯文败类应助科研通管家采纳,获得10
30秒前
快乐寄风发布了新的文献求助10
30秒前
Lucas应助科研通管家采纳,获得10
30秒前
研友_VZG7GZ应助科研通管家采纳,获得10
30秒前
30秒前
充电宝应助chengzhiliu29采纳,获得30
31秒前
31秒前
妥妥酱完成签到 ,获得积分10
31秒前
32秒前
陆柒捌完成签到,获得积分20
33秒前
高分求助中
Sustainability in Tides Chemistry 2800
Kinetics of the Esterification Between 2-[(4-hydroxybutoxy)carbonyl] Benzoic Acid with 1,4-Butanediol: Tetrabutyl Orthotitanate as Catalyst 1000
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Very-high-order BVD Schemes Using β-variable THINC Method 568
Chen Hansheng: China’s Last Romantic Revolutionary 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3138546
求助须知:如何正确求助?哪些是违规求助? 2789451
关于积分的说明 7791402
捐赠科研通 2445869
什么是DOI,文献DOI怎么找? 1300682
科研通“疑难数据库(出版商)”最低求助积分说明 626058
版权声明 601079